ATNM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
35.0M
0
0
-100.0%
90.0K
0
Cost of Revenue
0
0
0
0
0
Gross Profit
35.0M
0
0
-100.0%
90.0K
0
Operating Expenses
7.4M
+26.0%
5.9M
-8.0%
6.4M
+10.9%
5.8M
-22.9%
7.5M
R&D
5.4M
+28.0%
4.2M
-2.2%
4.3M
+1.2%
4.2M
-12.9%
4.9M
SG&A
2.1M
+20.9%
1.7M
-19.6%
2.1M
+38.0%
1.5M
-41.5%
2.6M
Operating Income
27.6M
+567.0%
-5903000
+8.0%
-6414000
-12.7%
-5692000
+24.1%
-7503000
EBITDA
28.0M
+576.6%
-5874000
+14.3%
-6856000
-25.0%
-5486000
+23.2%
-7141000
Net Income
27.9M
+605.3%
-5522000
+7.0%
-5940000
-15.8%
-5131000
+25.4%
-6878000
EPS (Basic)
$0.89
+594.4%
$-0.18
+5.3%
$-0.19
-18.8%
$-0.16
+27.3%
$-0.22
EPS (Diluted)
$0.89
+594.4%
$-0.18
+5.3%
$-0.19
-18.8%
$-0.16
+27.3%
$-0.22
Shares (Diluted)
31.4M
+0.5%
31.2M
+0.1%
31.2M
+0.0%
31.2M
+0.0%
31.2M
Actinium Pharmaceuticals (ATNM) โ€” Financials